Aptagen, LLC
Advanced Glycation End Products (Clone 9) (ID# 7533)
DNA
Advanced Glycation End products (AGE)
Protein
1 pM (reported value)
N/A
N/A°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
5'-dApdGpdCpdTpdCpdApdGpdApdApdTpdGpdGpdApdTpdCpdCpdApdApdApdCpdGpdCpdTpdCpdApdTpdApdApdCpdTpdCpdApdCpdTpdCpdCpdApdTpdApdCpdTpdCpdApdCpdTpdTpdGpdCpdTpdGpdApdTpdTpdCpdGpdCpdCpdApdApdCpdApdApdCpdApdCpdApdCpdCpdCpdTpdTpdApdApdApdCpdApdGpdTpdCpdCpdCpdTpdTpdCpdGpdApdCpdApdTpdGpdApdGpdApdApdTpdTpdCpdGpdGpdCpdCpdGpdGpdApdTpdCp-3'
106
32346.02
1004700
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Higashimoto, Y., et al. "In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes." Microvascular Research, 74 (2007): 65-69.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.